O-32 - Novel agents

Co-Author(s)

• MA

  Mari Ariyasu, BPharm

  Senior Director
  Global Development
  Shionogi & Co., Ltd.
  Osaka, Osaka, Japan

  Disclosure: Shionogi & Co., Ltd. (Employee)
• AB

  Aklile Berhanu, PhD

  Scientist
  Genentech, Inc.
  South San Francisco, California

  Disclosure: Genentech, Inc. (Employee, Equity interest (Stock/Stock Options))
• JB

  Jane-Valeriane Boua, BS

  research aid
  Duke University
  Durham, North Carolina

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• MC

  Montserrat Carrasco-Triguero, Ph.D.

  Senior Scientist
  Genentech - South San Francisco - CA
  South San Francisco, California

  Disclosure: Genentech (Employee)
• TC

  Tom Chu, MD, PhD

  Senior Medical Safety Director
  Genetech, Inc.
  South San Francisco, California

  Disclosure: Genentech (Employee)
• JC

  Jessica Couch, PhD

  Director/Project Team Leader
  Genentech, Inc.
  Mill Valley, California

  Disclosure: Genentech (Employee, Shareholder)
• AD

  Andrew Davis, BS

  Bioinformatics Scientist
  JMI Laboratories
  North Liberty, Iowa

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• TD

  Timothy Doyle

  Lead Molecular Scientist
  JMI Laboratories
  North Liberty, Iowa

  Disclosure: Allergan (Research Grant or Support)Allergan (Research Grant or Support)Cipla Ltd. (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Pfizer (Research Grant or Support)Qpex Biopharma (Research Grant or Support)
• RE

  Roger Echols, MD

  Consultant
  Infectious Disease Drug Development Consulting LLC
  Easton, Connecticut

  Disclosure: Shionogi Inc. (Consultant)
• 

  Vance Fowler, Jr., MD, MHS

  Professor of Medicine
  Division of Infectious Diseases
  Duke University
  Durham, North Carolina

  Disclosure: Abbvie : Grant/Research Support (Status: Ongoing); Actavis : Grant/Research Support; Advanced Liquid Logics : Grant/Research Support; Affinergy : Consultant, Research Grant or Support; Affinium : Consultant; Allergan : Grant/Research Support; Ampliphi Biosciences : Consultant; Armata : Consultant (Status: Ongoing); Basilea : Consultant, Research Grant or Support; Bayer : Consultant, Consultant; C3J : Consultant; CARB-X : Consultant (Status: Ongoing); Cerexa : Consultant, Research Grant or Support; Contrafect : Consultant, Research Grant or Support; Cubist : Grant/Research Support; Debiopharm : Consultant; Destiny : Consultant; Durata : Consultant; Forest : Grant/Research Support; Genentech : Consultant, Research Grant or Support; ICBiome : Consultant (Status: Ongoing); Integrated Biotherapeutics : Consultant; Janssen : Consultant, Research Grant or Support; Karius : Grant/Research Support; Locus : Grant/Research Support; Medical Biosurfaces : Grant/Research Support; Medicines Co. : Consultant; Medimmune : Consultant, Research Grant or Support; Merck : Consultant, Research Grant or Support; NIH : Grant/Research Support; Novadigm : Consultant; Novartis : Consultant, Research Grant or Support; Pfizer : Grant/Research Support; Regeneron : Consultant, Research Grant or Support; Tetraphase : Consultant; Theravance : Consultant, Research Grant or Support; Valanbio : Board Member (Status: Ongoing), Other Financial or Material Support (Status: Ongoing), Stock options (Status: Ongoing); xBiotech : Consultant
• MH

  Meredith Hackel, PhD MPH

  Laboratory Director
  IHMA, Inc.
  Schaumburg, Illinois

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• WH

  Wouter Hazenbos, PhD

  Scientist
  1 DNA Way, Genentech, South San Francisco
  South San Francisco, California

  Disclosure: Genentech (Employee)
• MK

  Masahiro Kinoshita, MPharm

  Global MA Coordinator for ID area​
  Shionogi & Co., Ltd.
  Osaka, Osaka, Japan

  Disclosure: Shionogi & Co., Ltd. (Employee)
• NL

  Nicholas Lewin-Koh, PhD

  Statistician
  Genentech, Inc.
  South San Francisco, California

  Disclosure: Genentech (Employee)
• JL

  Jeremy Lim, PharmD

  Senior Clinical Scientist
  Genentech, Inc.
  South San Francisco, California

  Disclosure: Roche (Employee, Shareholder)
• JL

  Jill Lindley

  Drug Development Specialist
  JMI Laboratories
  North Liberty, Iowa

  Disclosure: Allergan (Research Grant or Support)Qpex Biopharma (Research Grant or Support)
• OL

  Olga Lomovskaya, PhD

  VP, Biology
  Qpex Biopharma
  San Diego, California

  Disclosure: Qpex Biopharma (Employee)
• CM

  Choiselle Marius, n/a

  Research Technician
  Neurosurgery
  Duke University
  Durham, North Carolina

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• JM

  Jose M Miro, MD PhD

  Dr.
  Infectious Diseases Service
  Hospital Clinic of Barelona
  Barcelona, Catalonia, Spain

  Disclosure: GENENTECH (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member)
• AM

  Adel Moussa, Ph.D.

  EVP, Chemistry
  Chemistry
  Atea Pharmaceuticals, Inc.
  Boston, Massachusetts

  Disclosure: Atea Pharmaceuticals, Inc. (Employee)
• TN

  Tsutae Den Nagata, MD

  Senior Vice President
  Global Development
  Shionogi & Co., Ltd.
  Osaka, Osaka, Japan

  Disclosure: Shionogi & Co., Ltd. (Employee)
• RN

  Rio Nakamura, BSc

  Senior Researcher
  Shionogi & Co., Ltd.
  Osaka, Osaka, Japan

  Disclosure: Shionogi & Co., Ltd.: Employee
• MO

  Merime Oota, BSc

  Senior Researcher
  Shionogi & Co., Ltd.
  Osaka, Osaka, Japan

  Disclosure: Shionogi & Co., Ltd. (Employee)
• JP

  Julia Palmucci, n/a

  PhD Student
  Molecular Genetics and Microbiology
  Duke University
  Durham, North Carolina

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• MP

  Melicent Peck, MD, PhD

  Lead Medical Director
  gRED
  Genentech
  South San Francisco, California

  Disclosure: Genentech (Employee)
• 

  John Perfect, MD

  Professor of Medicine
  Medicine
  Duke University
  Durham, North Carolina

  Disclosure: amplyx (Grant/Research Support)astellas (Grant/Research Support)astellas (Grant/Research Support)
• KP

  Keith Pietropaolo, B.A.

  VP, Clinical Operations and Project Management
  Clinical Operations and Project Management
  Atea Pharmaceuticals, Inc.
  Boston, Massachusetts

  Disclosure: Atea Pharmaceuticals, Inc. (Employee)
• CR

  Carrie Rosenberger, Ph.D.

  Senior Scientist
  Biomarker Discovery
  Genentech, Inc.
  South San Francisco, California

  Disclosure: Genentech (Employee, Shareholder)
• SR

  Sharon Rymut, PhD

  Associate Scientist
  Genentech
  San Francisco, California

  Disclosure: Genentech (Employee, Shareholder)
• DS

  Daniel Sahm, PhD

  VP Global Microbiology Services & Chief Scientific Officer
  IHMA, Inc.
  Schaumburg, Illinois

  Disclosure: IHMA (Employee)Pfizer, Inc. (Consultant)Shionogi & Co., Ltd. (Independent Contractor)
• QS

  Quinlyn Soltow, PhD

  Sr Manager, Analytical Science
  CMC
  Amplyx Pharmaceuticals
  San Diego, California

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• JS

  Jean-Pierre Sommadossi, Ph.D.

  Founder and CEO
  Atea Pharmaceuticals, Inc.
  Boston, Massachusetts

  Disclosure: Atea Pharmaceuticals, Inc. (Board Member)
• MT

  Miki Takemura, MS

  Associate Director, Laboratory for Drug Discovery and Disease Research
  Shionogi & Co., Ltd.
  Osaka, Osaka, Japan

  Disclosure: Shionogi & Co., Ltd. (Employee)
• JT

  Jennifer Tenor, PhD

  PhD
  Duke University
  Durham, North Carolina

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• DT

  Dena Toffaletti, PhD

  PhD
  Duke University
  Durham, North Carolina

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• KT

  Kiichiro Toyoizumi, PhD

  Principal Biostatistician
  Shionogi Inc
  Florham Park, New Jersey

  Disclosure: Shionogi & Co., Ltd. (Employee)
• 

  Yoshinori Yamano, PhD

  Chief Scientific Officer for Infectious Diseases
  Shionogi & Co., Ltd.
  Osaka, Osaka, Japan

  Disclosure: Shionogi & Co., Ltd. (Employee)
• XZ

  Xiao-Jian Zhou, Ph.D.

  EVP, Early Stage Development
  Clinical Sciences
  Atea Pharmaceuticals, Inc.
  Boston, Massachusetts

  Disclosure: Atea Pharmaceuticals, Inc. (Employee)

Presenting Author(s)

• 

  Mariana Castanheira, PhD

  Chief Scientific Officer
  JMI Laboratories
  North Liberty, IA

  Disclosure: 1928 Diagnostics (Research Grant or Support)A. Menarini Industrie Farmaceutiche Riunite S.R.L. (Research Grant or Support)Allergan (Research Grant or Support)Allergan (Research Grant or Support)Amplyx Pharmaceuticals (Research Grant or Support)Cidara Therapeutics (Research Grant or Support)Cidara Therapeutics (Research Grant or Support)Cipla Ltd. (Research Grant or Support)Cipla Ltd. (Research Grant or Support)Fox Chase Chemical Diversity Center (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Merck (Research Grant or Support)Merck (Research Grant or Support)Merck & Co, Inc. (Research Grant or Support)Merck & Co, Inc. (Research Grant or Support)Paratek Pharma, LLC (Research Grant or Support)Pfizer (Research Grant or Support)Qpex Biopharma (Research Grant or Support)

  Slides
• 

  Charles Giamberardino, Jr., MR

  Associate in Research
  Medicine/Infectious Diseases
  Duke University
  Durham, NC

  Disclosure: Box: Shareholder

  Slides Slides and Audio
• 

  Steven Good, M.S.

  EVP, Preclinical Sciences
  Preclinical Sciences
  Atea Pharmaceuticals, Inc.
  Boston, Massachusetts

  Disclosure: Atea Pharmaceuticals, Inc. (Employee)

  Slides Slides and Audio
• 

  Yuko Matsunaga, MD

  Medical Director
  Clinical Development
  Shionogi Inc.
  Florham Park, NJ

  Disclosure: Shionogi Inc. (Employee)

  Slides Slides and Audio
• 

  Loren Miller, MD, MPH

  Associate Chief
  Harbor UCLA
  Torrance, California

  Disclosure: genentech : Grant/Research Support; Merck : Grant/Research Support (Status: Ongoing)

  Slides Slides and Audio
• 

  Yuuta Ukai, MSc

  Senior Researcher
  Shionogi & Co., Ltd.
  Osaka, Osaka, Japan

  Disclosure: Shionogi & Co., Ltd.: Employee

  Slides Slides and Audio

Presentations:

• in Vitro Antibacterial Activity of Cefiderocol Against Non-fermenter Clinical Strains Collected in North America and Europe from Multinational Surveillance Studies SIDERO-WT-2014–2018
  Yuuta Ukai, MSc – Shionogi & Co., Ltd.; Rio Nakamura, BSc – Shionogi & Co., Ltd.; Merime Oota, BSc – Shionogi & Co., Ltd.; Meredith Hackel, PhD MPH – IHMA, Inc.; Roger Echols, MD – Infectious Disease Drug Development Consulting LLC; Miki Takemura, MS – Shionogi & Co., Ltd.; Yoshinori Yamano, PhD – Shionogi & Co., Ltd.; Daniel F. Sahm, PhD – IHMA, Inc.
• Cefiderocol Treatment for Serious Infections Caused by Carbapenem-resistant Bacteria: Post-hoc Analysis of Outcomes by Pathogen in the CREDIBLE-CR Study
  Yuko Matsunaga, MD – Shionogi Inc.; Mari Ariyasu, BPharm – Shionogi & Co., Ltd.; Miki Takemura, MS – Shionogi & Co., Ltd.; Yoshinori Yamano, PhD – Shionogi & Co., Ltd.; Kiichiro Toyoizumi, PhD – Shionogi Inc; Masahiro Kinoshita, MPharm – Shionogi & Co., Ltd.; Roger Echols, MD – Infectious Disease Drug Development Consulting LLC; Tsutae Den Nagata, MD – Shionogi & Co., Ltd.
• Activity of a Novel β-lactamase Inhibitor QPX7728 Combined With β-lactams Against st258 klebsiella Pneumoniae and st131 escherchia Coli Isolates Producing β-lactamases
  Mariana Castanheira, PhD – JMI Laboratories; Jill Lindley – JMI Laboratories; Timothy B. Doyle – JMI Laboratories; Andrew P. Davis, BS – JMI Laboratories; Olga Lomovskaya, PhD – Qpex Biopharma
• A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multiple-ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Patients with staphylococcus Aureus Bacteremia Receiving Standard-of-care Antibiotics
  Jeremy Lim, PharmD – Genentech, Inc.; Nicholas Lewin-Koh, PhD – Genentech, Inc.; Tom Chu, MD, PhD – Genetech, Inc.; Sharon M. Rymut, PhD – Genentech; Aklile Berhanu, PhD – Genentech, Inc.; Montserrat Carrasco-Triguero, Ph.D. – Genentech - South San Francisco - CA; Carrie C. Rosenberger, Ph.D. – Genentech, Inc.; Wouter L. Hazenbos, PhD – 1 DNA Way, Genentech, South San Francisco; Loren G. Miller, MD, MPH – Harbor UCLA; Vance G. Fowler, Jr., MD, MHS – Duke University; Jose M Miro, MD PhD – Hospital Clinic of Barelona; Jessica A. Couch, PhD – Genentech, Inc.; Melicent C. Peck, MD, PhD – Genentech
• Efficacy of the Novel gwt1 Inhibitor APX2039 in a Rabbit Model of cryptococcus Meningitis
  Charles D. Giamberardino, Jr., MR – Duke University; Quinlyn A. Soltow, PhD – Amplyx Pharmaceuticals; Jennifer Tenor, PhD – Duke University; Dena Toffaletti, PhD – Duke University; Jane-Valeriane Boua, BS – Duke University; Choiselle Marius, n/a – Duke University; Julia R. Palmucci, n/a – Duke University; John R. Perfect, MD – Duke University
• AT-752, an Oral Guanosine Nucleotide Prodrug, Exhibits Potent in Vitro Activity Against Flaviviruses and Prevents Disease Progression in a Dengue Mouse Model
  Steven S. Good, M.S. – Atea Pharmaceuticals, Inc.; Adel Moussa, Ph.D. – Atea Pharmaceuticals, Inc.; Xiao-Jian Zhou, Ph.D. – Atea Pharmaceuticals, Inc.; Jean-Pierre Sommadossi, Ph.D. – Atea Pharmaceuticals, Inc.; Keith Pietropaolo, B.A. – Atea Pharmaceuticals, Inc.